Renal and CVRM Biomarkers are no longer just scientific tools. They are strategic accelerators. Over the past several years, renal and cardiovascular-renal-metabolic (CVRM) drug development has undergone a quiet but profound shift. Biomarkers, principally renal and cardiorenal biomarkers — are no longer simply supportive or exploratory scientific readouts.
Back to Resource Center